Foamix initiated with a Buy at BofA/Merrill. BofA/Merrill analyst Jason Gerberry initiated Foamix with a Buy and $11 price target citing de-risked dermatology assets. Gerberry said Foamix offers two late-stage drugs with efficacy that are competitive to existing therapies but offer a topical alternative to widely used oral minocycline, with less safety baggage as a systemically absorbed drug. The analyst thinks FMX-101 and -103 will take market share and build recognition in the “experience-driven derm space.”
https://thefly.com/landingPageNews.php?id=2835769
https://thefly.com/landingPageNews.php?id=2835769
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.